Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsCareOregon Nucala Prior Auth Coverage | OpenPayer
    Ask Trek AI about this page
    CurrentCareOregon MedicaidPolicy N/A

    Nucala (mepolizumab) Prior Authorization

    Customize your policy alerts

    Sign up for all careoregon policy alerts

    Know when careoregon releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This guideline governs CareOregon Medicaid prior authorization for Nucala (mepolizumab) for eosinophilic COPD, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome, severe eosinophilic asthma, and chronic rhinosinusitis with nasal polyps. It establishes diagnosis-specific initial authorization and reauthorization requirements, documentation requirements, and approval durations for providers.

    Policy Summary
    PayerCareOregon Medicaid
    PolicyNucala (mepolizumab) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit medical records confirming that coverage criteria are met and prior authorization is approved before treatment.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    5Covered disease indications
    4, 6, or 12 monthsInitial authorization durations
    12 monthsReauthorization duration
    150 cells/uLCOPD and asthma eosinophil minimum

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    1,000 cells/uLHES eosinophil minimum
    4 mg/dayEGPA steroid maximum

    Indication-Specific Coverage Criteria

    Eosinophilic COPD initial therapy

    Covered when ALL of the following are met:

    Eosinophilic COPD initial authorization

    • Diagnosis of chronic obstructive pulmonary disease with eosinophilic phenotype.
    • Specialist: Prescribed by or in consultation with a pulmonologist.
    • Eosinophil count: Baseline eosinophil count is at least 150 cells/uL.>=150 cells/uL
    • Exacerbations and therapy: Medical records confirm at least 2 moderate or at least 1 severe COPD exacerbation within the last year despite adherence to inhaled LABA + LAMA + ICS triple therapy.>=2 moderate or >=1 severe exacerbations in the last year

    Eosinophilic COPD reauthorization

    Reauthorization requires the following:

    COPD continuation: Medical records confirm clinical improvement in COPD symptoms and/or a reduction in the frequency or severity of exacerbations.

    EGPA initial therapy

    Covered when ALL of the following are met:

    EGPA initial authorization

    • Diagnosis of eosinophilic granulomatosis with polyangiitis.
    • Specialist

      • Prescribed by or in consultation with a pulmonologist.
      • Prescribed by or in consultation with a rheumatologist.
      • Prescribed by or in consultation with a vasculitis specialist.
    • Systemic involvement: Medical records confirm systemic involvement beyond asthma and ear, nose, and throat manifestations.

    EGPA reauthorization

    Reauthorization requires ALL of the following:

    EGPA continuation

    • Disease response

      • Medical records confirm disease remission with a Birmingham Vasculitis Activity Score of 0.BVAS=0
      • Medical records confirm improvement in Birmingham Vasculitis Activity Score with reduced related hospitalizations, ED visits, or urgent care utilization since starting therapy.
    • Corticosteroid dose: Oral corticosteroid dose is less than or equal to 4 mg/day.<=4 mg/day

    HES initial therapy

    Covered when ALL of the following are met:

    HES initial authorization

    • Diagnosis: Medical records confirm PDGFRA-negative hypereosinophilic syndrome without an identifiable non-hematologic secondary cause.
    • Specialist: Prescribed by or in consultation with a hematologist.
    • Disease duration: Member has had HES for at least 6 months.>=6 months
    • Flare history: At least two HES flares occurred in the past 12 months while on hydroxyurea or corticosteroids.

    HES reauthorization

    Reauthorization requires documented response:

    HES response

    • Medical records show HES flares since starting therapy.
    • Medical records show another clinical response since starting therapy.

    Severe eosinophilic asthma initial therapy

    Covered when ALL of the following are met:

    Severe eosinophilic asthma initial authorization

    • Diagnosis: Medical records confirm moderate-to-severe asthma with eosinophilic phenotype.
    • Eosinophil count: Baseline eosinophil count is at least 150 cells/uL.>=150 cells/uL
    • Prior controller therapy: There has been trial and failure, intolerance, or contraindication to high-dose inhaled corticosteroid with long-acting beta-agonist, long-acting muscarinic antagonist, and leukotriene inhibitor.
    • Adherence:

    Severe eosinophilic asthma reauthorization

    Reauthorization requires documented clinical benefit:

    Asthma response

    • Medical records confirm reduction in asthma exacerbations.
    • Medical records confirm reduction in ED or urgent care visits.
    • Medical records confirm reduction in hospitalizations.
    • Medical records confirm reduced oral steroid requirements.
    • Medical records confirm sustained clinical improvement from baseline.

    Chronic rhinosinusitis with nasal polyps initial therapy

    Covered when ALL of the following are met:

    Nasal polyps initial authorization

    • Diagnosis and recurrence: Medical records confirm chronic rhinosinusitis with nasal polyps, inadequate response to nasal corticosteroids, and recurrent nasal polyps after multiple prior sinus surgeries.
    • Nasal corticosteroids: Medical records confirm failure of two nasal corticosteroids.2 nasal corticosteroids
    • Sinuva: Medical records confirm failure of Sinuva implant.
    • Adjunctive use: Member is currently adherent to nasal corticosteroids and Nucala is intended as adjunctive therapy to nasal corticosteroids.

    Chronic rhinosinusitis with nasal polyps reauthorization

    Reauthorization requires ALL of the following:

    Nasal polyp continuation

    • Clinical response: Medical records confirm clinically significant improvement in symptoms.
    • Surgery status: Member has not required sinus surgery for nasal polyps since starting Nucala therapy.

    Product Coding and Clinical Thresholds

    Nucala GPI/product codesmixedCovered
    4460405500D530Mepolizumab subcutaneous solution auto-injector 100 mg/mL — Brand
    4460405500E520Mepolizumab subcutaneous solution pref syringe 40 mg/0.4 mL — Brand
    4460405500E530Mepolizumab subcutaneous solution pref syringe 100 mg/mL — Brand
    44604055002120Mepolizumab for injection 100 mg — Brand
    Baseline eosinophil count
    Applicable indicationsEosinophilic COPD and severe eosinophilic asthma
    Minimum baseline eosinophil countAt least 150 cells/uL
    Measurement timingBaseline count required before initial authorization
    HES baseline eosinophil count
    Applicable indicationHypereosinophilic syndrome (HES)
    Minimum baseline eosinophil countAt least 1,000 cells/uL
    Measurement timing

    Prior Authorization and Documentation Actions

    Prior Authorization

    Eosinophilic COPD: Prior Authorization Required

    Prior authorization is required for Nucala for eosinophilic COPD. Initial authorization is approved for 6 months; reauthorization requires documentation of clinical benefit.

    • Prescribed by or in consultation with a pulmonologist.
    • Baseline eosinophil count must be at least 150 cells/uL.
    • Initial approval requires at least 2 moderate or at least 1 severe COPD exacerbation within the past year despite triple therapy.
    Prior Authorization

    EGPA: Prior Authorization and Specialist Documentation

    Prior authorization is required for Nucala for eosinophilic granulomatosis with polyangiitis (EGPA). The diagnosis, specialist involvement, systemic disease, and treatment history must be documented.

    • Prescribed by or in consultation with a pulmonologist, rheumatologist, or vasculitis specialist.
    • Document systemic involvement beyond asthma and ear, nose, or throat manifestations.

    Key Clinical Definitions

    Hypereosinophilic syndrome
    ConditionHypereosinophilic syndrome
    DefinitionHypereosinophilic syndrome without an identifiable non-hematologic secondary cause
    Authorization contextThis definition is used for Nucala coverage of HES
    PDGFRA-negative HES
    ConditionHypereosinophilic syndrome
    Molecular classificationPDGFRA-negative
    Documentation requirementMedical records must confirm a diagnosis of PDGFRA-negative HES

    Initial Authorization by Indication

    Eosinophilic COPD

    Initial therapy requires ALL of the following:

    • Diagnosis of chronic obstructive pulmonary disease with eosinophilic phenotype.
    • Prescribed by or in consultation with a pulmonologist.
    • Baseline eosinophil count is at least 150 cells/uL.>=150 cells/uL
    • Medical records confirm at least 2 moderate or at least 1 severe COPD exacerbation within the last year despite adherence to inhaled LABA + LAMA + ICS triple therapy.>=2 moderate or >=1 severe exacerbations in the last year

    Reauthorization and Clinical Response

    Indication-specific reauthorization response

    Continuation requires indication-specific evidence of clinical response:

    Indication-specific response

    • COPD: Document clinical improvement in COPD symptoms and/or reduced exacerbation frequency or severity.
    • EGPA

      • Disease response

        • Document disease remission with a Birmingham Vasculitis Activity Score of 0.BVAS=0
        • Document improvement in Birmingham Vasculitis Activity Score with reduced related hospitalizations, ED visits, or urgent care utilization since starting therapy.

    Required Prior Therapies

    StepRequired therapyFailure or qualification criteria
    1Inhaled LABA + LAMA + ICS triple therapyAt least 2 moderate or at least 1 severe COPD exacerbation within the last year despite adherence
    StepRequired therapyFailure or qualification criteria
    1Hydroxyurea and FasenraDisease flare while on hydroxyurea or contraindication/intolerance to hydroxyurea, and disease flare while on Fasenra or contraindication/intolerance to Fasenra
    StepRequired therapyFailure or qualification criteria
    1High-dose ICS/LABA, LAMA, and leukotriene inhibitorTrial and failure, intolerance, or contraindication to all specified therapies
    StepRequired therapyFailure or qualification criteria
    1Two nasal corticosteroids and Sinuva implantFailure of two nasal corticosteroids and Sinuva implant
    Policy Summary
    PayerCareOregon Medicaid
    PolicyNucala (mepolizumab) Prior Authorization
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit medical records confirming that coverage criteria are met and prior authorization is approved before treatment.
    SourceLink
    On This Page
    Indication-Specific Coverage CriteriaProduct Coding and Clinical ThresholdsPrior Authorization and Documentation ActionsKey Clinical DefinitionsInitial Authorization by IndicationReauthorization and Clinical ResponseRequired Prior Therapies
  1. Corticosteroid response: Medical records confirm failure to induce remission with oral or pulse corticosteroids or inability to taper oral corticosteroids after 3 months.
  2. Immunosuppressant response: Medical records confirm failure of an immunosuppressant, such as methotrexate, azathioprine, or cyclophosphamide.
  3. >=2 flares in 12 months
  4. Eosinophil count: Baseline eosinophil count is at least 1,000 cells/uL.>=1,000 cells/uL
  5. Corticosteroid response: Member has a positive response to corticosteroid therapy.
  6. Hydroxyurea status

    • Disease flare while on hydroxyurea.
    • Contraindication or intolerance to hydroxyurea.
  7. Fasenra status

    • Disease flare while on Fasenra.
    • Contraindication or intolerance to Fasenra.
  8. Member is adherent to maintenance inhaler(s) and leukotriene therapy.

    Consistent fill history may be used to document adherence.

  9. Utilization or exacerbations: Member has had an urgent care visit, ED visit, hospitalization, or frequent exacerbations within the last 12 months.within 12 months
  10. Surgery status: Provider attests that the member is at risk of another sinus surgery but is not a candidate for sinus surgery.
  11. Baseline count required for initial authorization
    COPD exacerbation history
    Moderate exacerbationsAt least 2 moderate COPD exacerbations
    Severe exacerbationsAt least 1 severe COPD exacerbation may qualify
    Time period and treatment contextWithin the last year despite adherence to inhaled LABA + LAMA + ICS triple therapy
    EGPA corticosteroid response
    Corticosteroid requirementUnable to taper oral corticosteroids after 3 months
    Alternative corticosteroid criterionFailure to induce remission with oral or pulse corticosteroids
    Applicable indicationEosinophilic granulomatosis with polyangiitis (EGPA) initial authorization
    HES disease duration
    Applicable indicationHypereosinophilic syndrome (HES)
    Minimum duration since diagnosisAt least 6 months
    Authorization stageInitial authorization
    HES flare history
    Minimum flare frequencyAt least 2 HES flares
    Lookback periodDuring the past 12 months
    Treatment contextFlares must occur while on hydroxyurea or corticosteroids
    EGPA oral corticosteroid dose
    Applicable indicationEosinophilic granulomatosis with polyangiitis (EGPA)
    Maximum oral corticosteroid doseLess than or equal to 4 mg/day
    Authorization stageReauthorization
    EGPA disease activity
    Remission thresholdBirmingham Vasculitis Activity Score of 0
    Alternative responseImprovement in Birmingham Vasculitis Activity Score with reduced related hospitalizations, ED visits, or urgent care utilization
    Applicable indication and stageEGPA reauthorization
  12. Document failure to induce remission with oral or pulse corticosteroids, or inability to taper oral corticosteroids after 3 months.
  13. Initial approval requires failure of an immunosuppressant.
  14. Prior Authorization

    HES: Prior Authorization and Approval Duration

    Prior authorization is required for Nucala for hypereosinophilic syndrome (HES) without an identifiable non-hematologic secondary cause. Initial authorization is approved for 6 months; reauthorization is approved for 12 months when response criteria are met.

    • Initial approval requires PDGFRA-negative HES, hematologist involvement, a diagnosis for at least 6 months, and at least 2 HES flares in the past 12 months while receiving hydroxyurea or corticosteroids.
    • Baseline eosinophil count must be at least 1,000 cells/uL, with a positive response to corticosteroids.
    • Reauthorization requires documentation of HES remission or other clinical response.
    Prior Authorization

    Severe Eosinophilic Asthma: Authorization Duration

    Prior authorization is required for Nucala for severe eosinophilic asthma. Initial authorization is approved for 6 months and reauthorization is approved for 12 months when response is documented.

    • Initial approval requires moderate-to-severe asthma, baseline eosinophils of at least 150 cells/uL, required prior controller therapy, adherence, and qualifying recent utilization or exacerbations.
    • Reauthorization requires documentation of reduced exacerbations, acute-care use, hospitalizations, oral steroid requirements, or sustained clinical improvement.
    Prior Authorization

    Nasal Polyps: Authorization and Reauthorization

    Prior authorization is required for Nucala for chronic rhinosinusitis with nasal polyps and inadequate response to nasal corticosteroids. Initial authorization is approved for 4 months; reauthorization is approved for 12 months when continued benefit is documented.

    • Initial approval requires recurrent nasal polyps after multiple prior sinus surgeries and failure of two nasal corticosteroids and a Sinuva implant.
    • Nucala must be used as adjunctive therapy with current nasal corticosteroid adherence.
    • Reauthorization requires clinically significant symptom improvement and no sinus surgery for nasal polyps since starting Nucala.

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: step_therapy

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Eosinophilic phenotype
    PhenotypeEosinophilic disease phenotype
    Required documentationDocumented eosinophilic disease characteristics and eosinophil counts
    Covered applicationsEosinophilic COPD and severe eosinophilic asthma

    EGPA

    Initial therapy requires ALL of the following:

    • Diagnosis of eosinophilic granulomatosis with polyangiitis.
    • Specialist involvement

      • Prescribed by or in consultation with a pulmonologist.
      • Prescribed by or in consultation with a rheumatologist.
      • Prescribed by or in consultation with a vasculitis specialist.
    • Medical records confirm systemic involvement beyond asthma and ear, nose, and throat manifestations.
    • Medical records confirm failure to induce remission with oral or pulse corticosteroids or inability to taper oral corticosteroids after 3 months.
    • Medical records confirm failure of an immunosuppressant, such as methotrexate, azathioprine, or cyclophosphamide.

    Hypereosinophilic syndrome

    Initial therapy requires ALL of the following:

    • Medical records confirm PDGFRA-negative hypereosinophilic syndrome without an identifiable non-hematologic secondary cause.
    • Prescribed by or in consultation with a hematologist.
    • Member has had HES for at least 6 months.>=6 months
    • At least two HES flares occurred in the past 12 months while on hydroxyurea or corticosteroids.>=2 flares in 12 months
    • Baseline eosinophil count is at least 1,000 cells/uL.>=1,000 cells/uL
    • Member has a positive response to corticosteroid therapy.
    • ANY of the following

      • Disease flare while on hydroxyurea.
      • Contraindication or intolerance to hydroxyurea.
    • ANY of the following

      • Disease flare while on Fasenra.
      • Contraindication or intolerance to Fasenra.

    Severe eosinophilic asthma

    Initial therapy requires ALL of the following:

    • Medical records confirm moderate-to-severe asthma with eosinophilic phenotype.
    • Baseline eosinophil count is at least 150 cells/uL.>=150 cells/uL
    • There has been trial and failure, intolerance, or contraindication to high-dose inhaled corticosteroid with long-acting beta-agonist, long-acting muscarinic antagonist, and leukotriene inhibitor.
    • Member is adherent to maintenance inhaler(s) and leukotriene therapy.

      Consistent fill history may be used to document adherence.

    • Member has had an urgent care visit, ED visit, hospitalization, or frequent exacerbations within the last 12 months.within 12 months

    Chronic rhinosinusitis with nasal polyps

    Initial therapy requires ALL of the following:

    • Medical records confirm chronic rhinosinusitis with nasal polyps, inadequate response to nasal corticosteroids, and recurrent nasal polyps after multiple prior sinus surgeries.
    • Medical records confirm failure of two nasal corticosteroids.2 nasal corticosteroids
    • Medical records confirm failure of Sinuva implant.
    • Member is currently adherent to nasal corticosteroids and Nucala is intended as adjunctive therapy to nasal corticosteroids.
    • Provider attests that the member is at risk of another sinus surgery but is not a candidate for sinus surgery.
  15. Oral corticosteroid dose is less than or equal to 4 mg/day.<=4 mg/day
  16. HES

    • Document HES flares since starting therapy.
    • Document another clinical response since starting therapy.
  17. Severe eosinophilic asthma

    • Document reduced asthma exacerbations, ED or urgent care visits, hospitalizations, oral steroid requirements, or sustained clinical improvement from baseline.
  18. Chronic rhinosinusitis with nasal polyps

    • Document clinically significant improvement in symptoms.
    • Member has not required sinus surgery for nasal polyps since starting Nucala therapy.